identification of predictive blood biomarkers of recurrent urinary tract infections

Conditions: Urinary Tract Infections

Summary: urinary tract infections affect more than 130 million people worldwide each year. almost 50% of women will have at least one urinary tract infection during their lifetime, usually cystitis. half of them will have recurrent cystitis. antibiotics are the first-line treatment for cystitis, but their effectiveness is decreasing due to the rapid spread of multi-resistant uro-pathogenic bacteria. the objective of this study is to identify blood biomarkers associated with a high risk of recurrent cystitis. immune system cells, and more specifically innate immunity cells, play a key role in controlling urinary tract infections. in addition, clinical studies have shown that there is a high inter-individual variability in the ability of innate immune cells to respond to different stimuli. we therefore hypothesized that there was an association between the risk of recurrent cystitis and a deficiency of certain immune cell types in producing certain pro-inflammatory cytokines, including tnf-α, in response to one or more bacterial stimuli, particularly flagellin.


Eligibility criteria:
inclusion criteria: * female aged 18 to 28 years; * subject accepting to be serologically tested for hiv and hcv; * subject considered healthy by the physician on the basis of medical history and clinical examination; * subject with a body mass index between 18.5 and 30 kg/m2; * subject understands and speaks french and is able to give written consent; * subject affiliated to social security or a similar regime; * having reported a single cystitis since the age of 14 (group 1), or 3 or more cystitis over a 12-month period since the age of 14 (group 2). exclusion criteria: * subject protected by law under guardianship or curatorship, or unable to participate in a clinical study under article l. 1121-16 of the french public health code; * subject who has participated in a clinical research study in the last 3 months in which he/she was exposed to a pharmaceutical product or medical device; * subject who has stayed in a tropical or subtropical country in the last 3 months; * pregnant or breastfeeding subject for women of childbearing age; * subject with special diet for medical reasons and prescribed by a doctor or dietician (e.g. a low-calorie diet or a diet intended to lower cholesterol levels); * subject who regularly consumes large quantities of alcohol, i. e. more than 50 g of pure alcohol per day (e. g. more than 4 glasses of 150 ml wine, more than 4 pints of 250 ml beer, or more than 4 glasses of 40 ml containing strong alcohol); * subject who has used an illegal recreational drug in the past 3 months; * subject who has taken an immunosuppressive or immunomodulatory drug (excluding intranasally or topically administered corticosteroids) in the past 2 weeks, or for more than 14 consecutive days in the past 6 months; * subject who has been vaccinated within the last 3 months; * subject who received a blood transfusion or immunoglobulins in the last 3 months; * subject stating that he has not been fasting for at least 10 hours; * subject reporting hiv or hcv status; * subject who had an infectious episode or was treated with antibiotics during the 4 weeks prior to the visit; * subject with a positive urinary pregnancy test; * subject with a severe and/or chronic and/or recurrent pathology, in particular: * a chronic inflammatory and/or autoimmune or allergic disease and in particular a chronic inflammatory disease of the intestine (crohn's disease, ulcerative colitis), epidermis (psoriasis, atopic dermatitis), joints (rheumatoid arthritis), nervous system (multiple sclerosis), type i diabetes; * high blood pressure or type ii diabetes; * a neurodegenerative disease. * subject who has been diagnosed with cancer and has not been in remission for more than 5 years.